Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-08-19, Stock:ABBV, The news for the past five days is as follows:
2019-08-12: NEWS1: 10 Medical Marijuana Stocks to Cure Your Portfolio.NEWS2: 10 Medical Marijuana Stocks to Cure Your Portfolio.NEWS3: SDY, AMCA: Big ETF Outflows.NEWS4: SDY, AMCA: Big ETF Outflows.NEWS5: 3M Stock Isn’t Crumbling, but It’s No Bargain Either.NEWS6: 5 Big Pharma Showdowns to Watch.
2019-08-13: NEWS1: Should Value Investors Consider AbbVie (ABBV) Stock Now?.NEWS2: Should Value Investors Consider AbbVie (ABBV) Stock Now?.NEWS3: Should Value Investors Consider AbbVie (ABBV) Stock Now?.NEWS4: 5 Biggest New Drugs Approved in 2019 So Far.NEWS5: 5 Biggest New Drugs Approved in 2019 So Far.NEWS6: 5 Biggest New Drugs Approved in 2019 So Far.NEWS7: JPMorgan Chase set to scoop record fee for Allergan sale.
2019-08-14: NEWS1: Oversold Conditions For AbbVie (ABBV).NEWS2: Oversold Conditions For AbbVie (ABBV).NEWS3: How Tesla has Become Most Profitable Short Bet at $2.75 Billion.NEWS4: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS5: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS6: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS7: Correction: Allergan sale.NEWS8: Defensive Stocks on Sale.NEWS9: Elliott bags Goldman’s Barg.
2019-08-15: NEWS1: The Top Pharma Stocks for 2019.NEWS2: 13 High-Yield Dividend Stocks to Watch.NEWS3: 5 Top Cancer-Fighting Stocks to Buy Now.NEWS4: 5 Top Cancer-Fighting Stocks to Buy Now.NEWS5: 5 Top Cancer-Fighting Stocks to Buy Now.
2019-08-16: NEWS1: How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit.NEWS2: How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals.NEWS3: FDA approves AbbVie's Rinvoq to treat moderate-to-severe RA.NEWS4: UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr.NEWS5: AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis.NEWS6: Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe.NEWS7: Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe.NEWS8: Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe.

Answer: Rise